Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V

Go back to Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for V
(NASDAQ: IVVD) Delayed: 0.73 -0.08 (9.88%)
Previous Close $0.81    52 Week High $ 
Open $0.80    52 Week Low $ 
Day High $0.82    P/E N/A 
Day Low $0.73    EPS $ 
Volume 9,465,003